Cargando…

Correction: Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472148/ http://dx.doi.org/10.1136/jitc-2021-004479corr1

Ejemplares similares

Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
por: Martín-Otal, Celia, et al.
Publicado: (2022)

CAR-T-Cell Therapy for Solid Tumors Positive for Fibronectin Extra Domain B
por: Zhang, Zhijie, et al.
Publicado: (2022)

Human fibronectin extra domain B as a biomarker for targeted therapy in cancer
por: Lieverse, Relinde I. Y., et al.
Publicado: (2020)

Expression of Fibronectin Isoforms in Human Breast Tissue: Production of Extra Domain A(+)/Extra Domain B(+) by Cancer Cells and Extra Domain A(+) by Stromal Cells
por: Matsumoto, Ei‐ichi, et al.
Publicado: (1999)

MRI of Breast Tumor Initiating Cells Using the Extra Domain-B of Fibronectin Targeting Nanoparticles
por: Sun, Yujin, et al.
Publicado: (2014)

Correction to ‘The roles of T-cell competition and stochastic extinction events in CAR T-cell therapy’
por: Kimmel, Gregory J., et al.
Publicado: (2022)

Fibronectin Extra Domain A Promotes Liver Sinusoid Repair following Hepatectomy
por: Sackey-Aboagye, Bridget, et al.
Publicado: (2016)

Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma
por: Saw, Phei Er, et al.
Publicado: (2021)

Publisher Correction: Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy
por: Vedvyas, Yogindra, et al.
Publicado: (2020)

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, D., et al.
Publicado: (2018)

Correction: Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy
Publicado: (2023)

Expression of extra domain A fibronectin sequence in vascular smooth muscle cells is phenotype dependent
Publicado: (1989)

Fibroblast-like synovial cell production of extra domain A fibronectin associates with inflammation in osteoarthritis
por: Kragstrup, Tue W., et al.
Publicado: (2019)

Lack of Fibronectin Extra Domain A Alternative Splicing Exacerbates Endothelial Dysfunction in Diabetes
por: Gortan Cappellari, Gianluca, et al.
Publicado: (2016)

Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin
por: Zhang, Zhijie, et al.
Publicado: (2023)

Correction to: Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
por: Marofi, Faroogh, et al.
Publicado: (2021)

Fibronectin extra domain a limits liver dysfunction and protects mice during acute inflammation()
por: Venu, Vivek Krishna Pulakazhi, et al.
Publicado: (2023)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Correction: PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
Publicado: (2022)

Author Correction: Engineering Axl specific CAR and SynNotch receptor for cancer therapy
por: Cho, Jang Hwan, et al.
Publicado: (2020)

Correction: Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
por: Dagar, Gunjan, et al.
Publicado: (2023)

Correction: Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
Publicado: (2014)

Correction to: In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy
por: Śledź, Marta, et al.
Publicado: (2023)

Correction: Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
Publicado: (2021)

Fibronectin containing alternatively spliced extra domain A interacts at the central and c-terminal domain of Toll-like receptor-4
por: Gupta, Shubhangi, et al.
Publicado: (2022)

Author Correction: LRP1 is required for novobiocin-mediated fibronectin turnover
por: Boel, Natasha Marie-Eraine, et al.
Publicado: (2020)

Correction to: An update on extra-oral bitter taste receptors
por: Tuzim, Kamila, et al.
Publicado: (2021)

Correction to: Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review
por: Pensato, Umberto, et al.
Publicado: (2022)

Correction: Full-Length Fibronectin Drives Fibroblast Accumulation at the Surface of Collagen Microtissues during Cell-Induced Tissue Morphogenesis
Publicado: (2016)

Correction: Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor
por: Zhang, Zhiwei, et al.
Publicado: (2020)

Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
por: Hou, Jiangxue, et al.
Publicado: (2023)

Cellular Fibronectin Containing Extra Domain A Causes Insulin Resistance via Toll-like Receptor 4
por: Rajak, Sangam, et al.
Publicado: (2020)

Correction: Smad3-dependent CCN2 mediates fibronectin expression in human skin dermal fibroblasts
Publicado: (2017)

Correction: αv-Class integrin binding to fibronectin is solely mediated by RGD and unaffected by an RGE mutation
por: Benito-Jardón, María, et al.
Publicado: (2020)

Irigenin, a novel lead from Western Himalayan chemiome inhibits Fibronectin-Extra Domain A induced metastasis in Lung cancer cells
por: Amin, Asif, et al.
Publicado: (2016)

Correction: A Biosynthetic Nerve Guide Conduit Based on Silk/SWNT/Fibronectin Nanocomposite for Peripheral Nerve Regeneration
por: Mottaghitalab, Fatemeh, et al.
Publicado: (2013)

Correction: Robust CAR-T memory formation and function via hematopoietic stem cell delivery
por: Zhen, Anjie, et al.
Publicado: (2021)

Correction to: ICU-outcomes in CAR-T patients—A single centre experience
por: Materski, T., et al.
Publicado: (2021)

Correction to: Extra energy for hearts with a genetic defect: ENERGY trial
por: van Driel, B. O., et al.
Publicado: (2019)

Correction: Constitutive Association of Tie1 and Tie2 with Endothelial Integrins is Functionally Modulated by Angiopoietin-1 and Fibronectin
por: Dalton, Annamarie C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_97nntvho3pgbl1l26au9m80cj1